201 related articles for article (PubMed ID: 37200859)
61. Regulation of bcl-xL expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM crosslinking and IL-4.
Koizumi T; Wang J; Suzuki Y; Masuda K; Watanabe T
Mol Immunol; 1996 Nov; 33(16):1247-53. PubMed ID: 9129161
[TBL] [Abstract][Full Text] [Related]
62. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells.
Schattner EJ; Mascarenhas J; Bishop J; Yoo DH; Chadburn A; Crow MK; Friedman SM
Blood; 1996 Aug; 88(4):1375-82. PubMed ID: 8695856
[TBL] [Abstract][Full Text] [Related]
63. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
64. Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily.
Kucka K; Wajant H
Front Cell Dev Biol; 2020; 8():615141. PubMed ID: 33644033
[TBL] [Abstract][Full Text] [Related]
65. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
66. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
Holzinger A; Abken H
Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
[TBL] [Abstract][Full Text] [Related]
67. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
[TBL] [Abstract][Full Text] [Related]
68. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
69. Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions.
Clement MV; Stamenkovic I
J Exp Med; 1994 Aug; 180(2):557-67. PubMed ID: 7519240
[TBL] [Abstract][Full Text] [Related]
70. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway.
Li Z; Xu Q; Peng H; Cheng R; Sun Z; Ye Z
Int Immunopharmacol; 2011 Apr; 11(4):496-503. PubMed ID: 21238618
[TBL] [Abstract][Full Text] [Related]
71. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
72. Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex.
Sharma V; Tewari R; Sk UH; Joseph C; Sen E
Int J Cancer; 2008 Nov; 123(9):2204-12. PubMed ID: 18709644
[TBL] [Abstract][Full Text] [Related]
73. p38 mitogen-activated protein kinase and nuclear factor-κB facilitate CD40-mediated salivary epithelial cell death.
Ping L; Ogawa N; Zhang Y; Sugai S; Masaki Y; Weiguo X
J Rheumatol; 2012 Jun; 39(6):1256-64. PubMed ID: 22505709
[TBL] [Abstract][Full Text] [Related]
74. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells.
Tong AW; Seamour B; Chen J; Su D; Ordonez G; Frase L; Netto G; Stone MJ
Leuk Lymphoma; 2000 Feb; 36(5-6):543-58. PubMed ID: 10784400
[TBL] [Abstract][Full Text] [Related]
75. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
An S; Yap D; Knox KA
Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
[TBL] [Abstract][Full Text] [Related]
76. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
[TBL] [Abstract][Full Text] [Related]
77. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
[TBL] [Abstract][Full Text] [Related]
78. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
Elife; 2023 Feb; 12():. PubMed ID: 36779699
[TBL] [Abstract][Full Text] [Related]
79. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
[TBL] [Abstract][Full Text] [Related]
80. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction.
Wajant H; Johannes FJ; Haas E; Siemienski K; Schwenzer R; Schubert G; Weiss T; Grell M; Scheurich P
Curr Biol; 1998 Jan; 8(2):113-6. PubMed ID: 9427646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
